Clinical progress, a proposed U.S. research initiative and vaccine licensing economics strengthen the bull case.
Biotechnology investors are finding fresh reasons to look beyond the pandemic trade. Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX) and Merck (NYSE: MRK) rallied on October 9 as…
Two new funds, institutional backing and a pharmaceutical heavyweight give the European life sciences investor fresh capital to turn promising science into investable businesses.
Biotechnology has never suffered from a shortage of ambitious ideas. Financing them is another matter. Forbion has just…
Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…
